Je was op zoek naar: mieloproliferatīviem (Lets - Engels)

pacientiem ar mieloproliferatīviem traucējumiem hidroksikarbamīda terapijas laikā ir konstatētas toksiskas ietekmes uz ādas asinsvadiem izpausmes, tostarp čūlas un gangrēna.
cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred in patients with myeloproliferative disorders during therapy with hydroxycarbamide.

hroniska mielomonocitāra leikoze (hmml) ar 10- 29% blastu šūnām kaulu smadzenēs bez mieloproliferatīviem traucējumiem;
chronic myelomonocytic leukaemia (cmml) with 10-29% marrow blasts without myeloproliferative disorder,

18 nomākumu/ toksicitāti anamnēzē, pacientiem ar blakusslimību, staru vai ķīmijterapijas izraisītu kaulu smadzeņu nomākumu un pacientiem ar hipereozinofiliju vai mieloproliferatīvu slimību.
18 caution should be exercised in patients with low leukocyte and/ or neutrophil counts for any reason, in patients receiving medicines known to cause neutropenia, in patients with a history of drug-induced bone marrow depression/ toxicity, in patients with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with myeloproliferative disease.